No Data
No Data
Elevation Oncology Initiated at Overweight by Stephens & Co.
Elevation Oncology Initiated at Overweight by Stephens & Co.
Stephens & Co. Initiates Coverage On Elevation Oncology With Overweight Rating, Announces Price Target of $8
Stephens & Co. analyst Sudan Loganathan initiates coverage on Elevation Oncology (NASDAQ:ELEV) with a Overweight rating and announces Price Target of $8.
12 Health Care Stocks Moving In Monday's After-Market Session
GainersAesthetic Medical Intl (NASDAQ:AIH) shares moved upwards by 23.3% to $0.57 during Monday's after-market session. The market value of their outstanding shares is at $27.0 million. Harrow (NASDAQ
Analysts Offer Insights on Healthcare Companies: PROCEPT BioRobotics (PRCT), Amgen (AMGN) and Elevation Oncology (ELEV)
Elevation Oncology to Present at the Citizens JMP Life Sciences Conference
Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to...
Wedbush: Reiterates Elevation Oncology (ELEV.US) rating and adjusted from superior to superior market rating, target price of $8.00.
Wedbush: Reiterates Elevation Oncology (ELEV.US) rating and adjusted from superior to superior market rating, target price of $8.00.